LANCE Ultra Total ERK 1/2 kits are designed for the detection of total (phosphorylated and non-phosphorylated) ERK1 and ERK2 in cell lysates using a simple, homogeneous LANCE Ultra assay (no wash steps). This assay can be used as a normalization assay for phospho-ERK detection, and is compatible with both adherent and suspension cells.
false falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please note control lysates are NOT included in the kits. Control lysates are sold separately, catalog number TRF4000S.
Formats:
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are homogeneous (no wash) TR-FRET (time-resolved fluorescence resonance energy transfer) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second antibody is labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Data are represented as ratiometric (665/615 nm X 10,000).
ERK1 and ERK2, also known as MAP Kinase 3 and MAP Kinase 1, are serine/threonine kinases and important targets for cancer treatment. ERK kinases are dually phosphorylated at Tyr-202 and Tyr-204, leading to activation of the target. ERK can also be dephosphorylated at Tyr-202 by PTPRJ. A number of downstream targets have been identified including EIF4EBP1, which is necessary for the initiation of translation. It has also been shown to phosphorylate ELK-1.
分析途徑 | MAPK |
---|---|
檢測目標 | ERK1/2 |
檢測目標類 | Protein |
自動化兼容 | Yes |
檢測方法 | Time-Resolved Fluorescence (TRF), TR-FRET |
產品品牌名稱 | LANCE Ultra |
運輸條件 | 藍冰 |
治療領域 | Neuroscience, Cardiovascular, Metabolic |
產品尺寸 | 500 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...